Revenue: The sum of all revenue fields included for a company's operating activities.
Ultragenyx Pharmaceutical Inc. (RARE) had Revenue of $207.28M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
|
Revenue |
$207.28M |
$-128.56M |
|
$29.34M |
|
$177.93M |
|
$320.56M |
|
$-113.28M |
|
$-14.40M |
|
$-127.69M |
|
$-127.69M |
|
$-128.56M |
|
$-128.56M |
|
$-128.56M |
|
$-128.56M |
|
$-113.28M |
|
$-105.01M |
|
98.60M |
|
98.60M |
|
$-1.28 |
|
$-1.28 |
|
| Balance Sheet Financials | |
$951.00M |
|
$244.00M |
|
$581.00M |
|
$1.53B |
|
$384.00M |
|
-- |
|
$1.23B |
|
$1.61B |
|
$-80.00M |
|
$-300.00M |
|
$-80.00M |
|
96.60M |
|
| Cash Flow Statement Financials | |
$-466.00M |
|
$236.00M |
|
$478.00M |
|
$184.00M |
|
$436.00M |
|
$252.00M |
|
$153.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
85.84% |
|
-54.65% |
|
-54.65% |
|
-- |
|
-61.60% |
|
-62.02% |
|
$-472.00M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.56 |
|
1.31 |
|
68.60 |
|
160.69% |
|
42.85% |
|
-8.39% |
|
160.69% |
|
$-0.83 |
|
$-4.79 |
|
$-4.73 |
|